NOTCH1 mutations in ~10-15% of MCL — adverse prognostic; not directly targeted. BTKi-base...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-NOTCH1-ACTIVATING-MCL |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-MCL |
| Sources | SRC-CIVIC SRC-ESMO-MCL-2024 SRC-NCCN-BCELL-2025 |
Actionability Facts
| Biomarker | BIO-NOTCH1-MUTATION |
|---|---|
| Variant | activating (PEST / HD) |
| Disease | DIS-MCL |
| ESCAT tier | IIIB |
| Evidence summary | NOTCH1 mutations in ~10-15% of MCL — adverse prognostic; not directly targeted. BTKi-based 1L (acalabrutinib + R) or BR + autoSCT per fitness/TP53. |
Notes
ESCAT IIIB. Often co-occurs with TP53; may flag for early CAR-T at relapse.
Used By
No reverse references found in the YAML corpus.